M161 M161 (Didanosine Delayed Release 250 mg)
Pill with imprint M161 M161 is Yellow, Capsule-shape and has been identified as Didanosine Delayed Release 250 mg. It is supplied by Mylan Pharmaceuticals Inc..
Didanosine is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for M161 M161
Didanosine Delayed Release
- Imprint:
- M161 M161
- Strength:
- 250 mg
- Color:
- Yellow
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Mylan Pharmaceuticals Inc.
- Inactive Ingredients:
- ferrosoferric oxide
carboxymethylcellulose sodium
silicon dioxide
diethyl phthalate
gelatin
hypromelloses
methacrylic acid - methyl methacrylate copolymer (1:1)
propylene glycol
ferric oxide red
shellac
trisodium citrate dihydrate
sodium lauryl sulfate
sodium starch glycolate type A potato
magnesium silicate
titanium dioxide
ferric oxide yellow
potassium hydroxide
Note: Inactive ingredients may vary.
More about didanosine
- Didanosine Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
Consumer resources
- Didanosine
- Didanosine Delayed-Release Enteric-Coated Capsules
- Didanosine Oral Solution
- Didanosine (Advanced Reading)
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
